Industries > Pharma > Global Tuberculosis Treatment Drugs Market Report 2020-2030

Back to Pharma Reports

Global Tuberculosis Treatment Drugs Market Report 2020-2030

Forecasts & Analysis of Epidemiology by Regions (United States, Europe, Germany, France, Italy, Spain, UK, Japan & Rest of the World), by Regional Markets (North America, Latin America, Middle East & Africa, Asia & Asia Pacific), Plus Analysis of Leading Nations, by Therapies & Leading Companies in the Tuberculosis Treatment Drugs market

PUBLISHED: 01 April 2020

PAGES: 174

PRODUCT CODE: PHA0733

SUBMARKET: Therapeutic Drugs

SKU: PHA0733 Categories: Pharma, Therapeutic Drugs Tags: PHA0733, PHA0808, PHA1019, PHA1130

Tuberculosis (TB) is a major public health concern worldwide, with an estimated 10.0 million cases of tuberculosis in 2019, a number that has been relatively stable in recent years. It is interesting to see how WHO, and global companies have taken steps to end tuberculosis worldwide. The growing number of prevalence cases of Multi-Drug Resistant TB and cases of new and relapsed TB among the population of developing and under developing countries have.

Not only the development from the treatment point of view, but also the new development diagnostic tests will play an important role in shifting the dynamics of the tuberculosis market. More than 23 companies have formed an alliance with institutions in developing markets to support clinical therapeutic developments.

The Tuberculosis Treatment Drugs Market is growing at the noteworthy CAGR of 5.8% with the estimated market size of $1,080 million in 2020. Globally market is registered to grow at the CAGR of 5.8% from 2019 to 2020. Growing needs of anti-tuberculosis drugs, increase in multi drug resistance TB cases, government initiatives towards TB elimination and the increase in the pipeline drugs as well as the vaccines will drive the growth of the TB market from 2020 to 2030. In addition, increase in funding will further boost up the institutes and the companies for research in the high TB burden countries.

The Tuberculosis Treatment Drugs Market Report explains the findings of the research of the Tuberculosis treatment market developments and growth factors which is driving the market. It notes key findings and makes recommendations for action for the companies who are actively participating and involved in the R&D of the tuberculosis therapies.

• Understand the dynamics of TB market
• Epidemiology Forecast and Analysis Globally and Regionally
• Market Forecast & Analysis by Regions, By Nations, By Therapies & By Companies
• Promising Therapies in the pipeline
• Shift from generics to the effective TB therapies
• WHO initiatives to end Global TB
• Growing demand of effective therapies in developed/ developing countries
• High TB Burden countries and funding appropriations
• Effective Diagnostic Tests recently launched & under development

Leading Companies in the Tuberculosis Drugs Market:
• Johnson & Johnson
• Lupin Limited
• Macleods Pharmaceuticals Limited
• Pfizer
• Otsuka Pharmaceuticals

Buy our report today Global Tuberculosis Treatment Drugs Market Research: Forecasts & Analysis of Epidemiology by Regions (United States, Europe, Germany, France, Italy, Spain, UK, Japan & Rest of the World), by Regional Markets (North America, Latin America, Middle East & Africa, Asia & Asia Pacific), Plus Analysis of Leading Nations, by Therapies & Leading Companies. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1 Report Overview

1.1 Global Tuberculosis Treatment Drugs Market Overview

1.1.1 Global Tuberculosis Treatment Drugs Market Overview

1.1.2 Why You Should Read This Report

1.1.3 How This Report Delivers

1.1.4 Key Questions Answered by This Analytical Report

1.1.5 Who is This Report For?

1.1.6 Methodology

1.1.7 Frequently Asked Questions (FAQ)

1.1.8 Associated Visiongain Reports

1.1.9 About Visiongain

2 Tuberculosis (TB) Disease Background

2.1 Disease Definition

2.2 Transmission of TB

2.2.1 Factors that Determine the Probability of M. tuberculosis Transmission

2.2.2 Characteristics of TB patient associated with Infection

2.2.3 Environmental Factors that enhance the probability that M. tuberculosis will Be transmitted

2.3 Patient Subtypes

2.3.1 Latent TB (TB infection)

2.3.2 Active TB (TB disease)

2.3.3 Difference between Latent TB Infection (LTBI) and active TB Disease

2.4 Tuberculosis Symptoms

2.4.1 On the basis of Signs and Symptoms, TB can be further Classified into: -

2.4.2 Drug-Resistant TB (MDR and XDR)

2.4.3 Multidrug-Resistant TB

2.4.4 Extensively Drug-Resistant TB

2.5 Diagnosis

2.5.1 Diagnosis of Latent tuberculosis infection (LTBI)

2.5.2 Diagnosis of Active tuberculosis infection (ATBI)

2.5.3 Guidelines for Diagnosis from the ATS, IDSA, and Control of Disease Prevention & Control (CDC)

2.5.4 Diagnostic Pipeline

2.6 Treatments for Tuberculosis

2.6.1 Anti-Tuberculosis Drugs

2.6.2 Treatment Guidelines

2.6.3 Tuberculosis Vaccine

3 Tuberculosis Epidemiology Forecast 2019-2020

3.1 World Health Organization Estimates for 2018

3.2 The Global Tuberculosis Epidemiology (2019-2030)

3.3 The United States Tuberculosis Epidemiology (2019-2030)

3.4 The Europe Tuberculosis Epidemiology (2019-2030)

3.4.1 Germany Tuberculosis Epidemiology (2019-2030)

3.4.2 France Tuberculosis Epidemiology (2019-2030)

3.4.3 Italy Tuberculosis Epidemiology (2019-2030)

3.4.4 Spain Tuberculosis Epidemiology (2019-2030)

3.4.5 The United Kingdom Tuberculosis Epidemiology (2019-2030)

3.5 Japan Tuberculosis Epidemiology (2019-2030)

3.6 ROW Tuberculosis Epidemiology (2019-2030)

3.7 30 High TB Burden Countries, 2020

4 Pipeline Drugs Analysis, 2020

4.1 Promising Therapies

4.1.1 Repurposed Drugs/Therapeutics

4.1.2 Current Regimen Trials

4.1.3 Pipeline Vaccine

5 Market Drivers & Barriers

5.1 Market Drivers Analysis

5.2 Global plan against drug-resistant TB drives diagnosis and treatment enrolment

5.3 Market Restraints Analysis

5.3.1 High Cost of Drugs

5.3.2 Poor regulation and lack of awareness in developing countries

5.4 SWOT Analysis of Tuberculosis Treatment Drugs Market

6 Global Tuberculosis Treatment Drugs Market Forecast by Regions 2019-2030

6.1 Leading Regional Markets 2020-2030

6.1.1 Geographical Breakdown of the Global Tuberculosis Drugs Market

6.1.2 Global Tuberculosis Drugs Market: Regional Forecast 2020-2030

6.1.3 How Will Regional Market Shares Change to 2030?

6.2 North America Tuberculosis Drugs Market 2020-2030

6.2.1 North America Tuberculosis Drugs Market: Forecast 2020-2030

6.3 Europe Tuberculosis Drugs Market 2020-2030

6.3.1 Europe Tuberculosis Drugs Market Forecast 2020-2030

6.4 Latin America Tuberculosis Drugs Market 2020-2030

6.4.1 Latin America Tuberculosis Drugs Market: Forecast 2020-2030

6.5 Middle East & Africa Tuberculosis Drugs Market 2020-2030

6.5.1 Middle East & Africa Tuberculosis Drugs Market: Forecast 2020-2030

6.6 Asia and Asia Pacific Tuberculosis Drugs Market 2020-2030

6.6.1 Asia and Asia Pacific Tuberculosis Drugs Market: Forecast 2020-2030

7 Global Tuberculosis Treatment Drugs Market Forecast by Therapies 2019-2030

7.1 First Line Tuberculosis Treatment Drugs Market 2019-2030

7.2 Second Line Tuberculosis Treatment Drugs Market 2019-2030

7.3 Tuberculosis Treatment Drugs Market by Therapies 2019-2030

7.3.1 Isoniazid Market Forecast 2020-2030

7.3.2 Rifampin Market Forecast 2020-2030

7.3.3 Other Drugs Market Forecast 2020-2030

8 Leading Companies in the Tuberculosis Drugs Market

8.1 Johnson & Johnson

8.1.1 Company Overview

8.1.2 Johnson & Johnson 2019 Therapeutics

8.1.3 Latest Developments Related to Key Marketed Products

8.1.4 Johnson & Johnson, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook

8.1.5 Johnson & Johnson, Revenue Forecast, 2020-2025

8.2 Lupin Limited

8.2.1 Company Overview

8.2.2 Lupin 2019 Therapeutics

8.2.3 Latest Developments Related to Key Marketed Products

8.2.4 Lupin, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook

8.2.5 Lupin, Revenue Forecast, 2020-2025

8.3 Macleods Pharmaceuticals Limited

8.3.1 Company Overview

8.3.2 Macleods Pharmaceuticals Limited 2019 Therapeutics

8.3.3 Latest Developments Related to Key Marketed Products

8.3.4 Macleods Pharmaceuticals Limited, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook

8.3.5 Macleods Pharmaceuticals Limited, Revenue Forecast, 2020-2025

8.4 Pfizer

8.4.1 Company Overview

8.4.2 Pfizer 2019 Therapeutics

8.4.3 Latest Developments Related to Key Marketed Products

8.4.4 Pfizer, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook

8.4.5 Pfizer, Revenue Forecast, 2020-2025

8.5 Otsuka Pharmaceuticals

8.5.1 Company Overview

8.5.2 Otsuka Pharmaceuticals 2019 Therapeutics

8.5.3 Latest Developments Related to Key Marketed Products

8.5.4 Otsuka Pharmaceuticals, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook

8.5.5 Otsuka Pharmaceuticals, Revenue Forecast, 2020-2025

9 Conclusions

9.1 Global Tuberculosis drugs Market in 2019, 2025 and 2030

9.1.1 Current Leading Tuberculosis Drugs Segments

9.1.2 Leading Tuberculosis drugs Companies

9.1.3 Leading Regional Markets

9.2 Global Tuberculosis Drugs Market Forecast 2020-2030

9.3 The Future of the Tuberculosis Drugs Market?

10 Associated Visiongain Reports

11 Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOS) 2020-2030

12 Visiongain Report Sales Order Form

12.1 About Visiongain

12.2 Visiongain report evaluation form

List of Tables

Table 1.1 Global Tuberculosis Treatment Drugs Market Overview, 2020-2030

Table 2.1 Key Facts about Tuberculosis

Table 2.2 Factors that Determine the Probability of Transmission of M. tuberculosis

Table 2.3 Difference between Latent TB Infection (LTBI) and TB Disease

Table 2.4 Testing of TB Infections

Table 2.5 Overview of progress in the development of TB diagnostics, August 2019

Table 2.6 Latent TB Infection Treatment Regimens

Table 2.7 Regimens for treating TB disease

Table 3.1 Global Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.2 Global Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.3 Global Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.4 Germany Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.5 France Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.6 Italy Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.7 Spain Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.8 The United Kindom Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.9 Japan Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.10 ROW Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Table 3.11 30 High TB Burden Countries, 2018

Table 4.1: 2019 Global New Drug TB Pipeline

Table 4.2: 2019 Repurposed/Existing Drug TB Pipeline

Table 4.3: 2019 Clinical Regimen Trials

Table 5.1 SWOT Analysis

Table 6.1 Global Tuberculosis drug Market by Product: Revenue ($m) and Market Share (%), 2019

Table 6.2 Global Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.3 Global Tuberculosis Drugs Market By Region: Revenues ($m) and Market Share(%), 2019 and 2030

Table 6.4 Global Tuberculosis Drugs Market Forecast by Region: Revenues ($m, AGR (%), and CAGR (%), 2019-2030

Table 6.5 North America Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030

Table 6.6 Tuberculosis Drugs Market Forecast by Countries: Revenues ($m, AGR (%), and CAGR (%), 2019-2030

Table 6.7 United States Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.8 Canada Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.9 Europe Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030

Table 6.10 Europe Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.11 Germany Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.12 France Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.13 Italy Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.14 Spain Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.15 United Kingdom Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.16 Latin America Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030

Table 6.17 Tuberculosis Drugs Market Forecast by Countries: Revenues ($m, AGR (%), and CAGR (%), 2019-2030

Table 6.18 Brazil Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.19 Mexico Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.20 Middle East & Africa Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030

Table 6.21 Tuberculosis Drugs Market Forecast by Countries: Revenues ($m, AGR (%), and CAGR (%), 2019-2030

Table 6.22 South Africa Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.23 Nigeria Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.24 Asia & Asia Pacific Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030

Table 6.25 Tuberculosis Drugs Market Forecast by Countries: Revenues ($m, AGR (%), and CAGR (%), 2019-2030

Table 6.26 India Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.27 China Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 6.28 China Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 7.1 First Line Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 7.2 Second Line Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 7.3 Tuberculosis Treatment Drugs Market by Therapies: Revenues ($m) and Market Share(%), 2019 and 2030

Table 7.4 Tuberculosis Treatment Isoniazid Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 7.5 Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 7.6 Tuberculosis Treatment Other Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Table 8.1 Johnson & Johnson: Company Overview, 2019

Table 8.2 Johnson & Johnson: Products Portfolio, 2019

Table 8.3 Johnson & Johnson: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Table 8.4 Lupin: Company Overview, 2019

Table 8.5 Lupin: Products Portfolio, 2019

Table 8.6 Lupin: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Table 8.7 Macleods Pharmaceuticals Limited: Company Overview, 2019

Table 8.8 Macleods Pharmaceuticals Limited: Products Portfolio, 2019

Table 8.9 Macleods Pharmaceuticals Limited: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Table 8.10 Pfizer: Company Overview, 2019

Table 8.11 Pfizer: Products Portfolio, 2019

Table 8.12 Pfizer: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Table 8.13 Otsuka Pharmaceuticals: Company Overview, 2019

Table 8.14 Otsuka Pharmaceuticals: Products Portfolio, 2019

Table 8.15 Otsuka Pharmaceuticals: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

List of Figures

Figure 2.1 Summary of recommendations for Latent tuberculosis infection (LTBI) Testing

Table 2.2 Summary of recommendations for LTBI Testing

Figure 3.1 Global Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.2 United States Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.3 Europe Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.4 Germany Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.5 France Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.6 Italy Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.7 Spain Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.8 The United Kindom Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.9 Japan Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 3.10 ROW Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000’s)

Figure 4.1 2019 Global New TB vaccine Pipeline

Figure 6.1 Global Tuberculosis drug Market By Regions: Market Share (%), 2019

Figure 6.2 Global Tuberculosis drug Market Size, By Region: Revenue($m), CAGR (%), 2019-2030

Figure 6.3 Global Tuberculosis drug Market Forecast: Revenue ($m) and AGR (%), 2019-2030

Figure 6.4 Global Tuberculosis Drugs Market By Region: Revenues ($m), 2019

Figure 6.5 Global Tuberculosis Drugs Market By Region: Revenues ($m), 2030

Figure 6.6 Global Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030

Figure 6.7 Global Tuberculosis Drugs Market By Region: Market Shares (%), 2019

Figure 6.8 Global Tuberculosis Drugs Market By Region: Market Shares (%), 2024

Figure 6.9 Global Tuberculosis Drugs Market By Region: Market Shares (%), 2030

Figure 6.10 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019

Figure 6.11 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030

Figure 6.12 North America Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030

Figure 6.13 U.S. Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.14 Canada Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.15 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019

Figure 6.16 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030

Figure 6.17 EUROPE Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.18 Germany Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.19 France Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.20 Italy Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.21 Spain Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.22 United Kingdom Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.23 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019

Figure 6.24 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030

Figure 6.25 Latin America Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030

Figure 6.26 Brazil Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.27 Mexico Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.28 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019

Figure 6.29 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030

Figure 6.30 Middle East & Africa Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030

Figure 6.31 South Africa Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.32 Nigeria Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.33 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019

Figure 6.34 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030

Figure 6.35 Asia and Asia Pacific Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030

Figure 6.36 India Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.37 China Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 6.38 Japan Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030

Figure 7.1 First Line Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Figure 7.2 Second Line Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Figure 7.3 Tuberculosis Drugs Market By Therapies: Revenues ($m), 2019

Figure 7.4 Tuberculosis Drugs Market By Therapies: Revenues ($m), 2030

Figure 7.5 Tuberculosis Treatment Isoniazid Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Figure 7.6 Tuberculosis Treatment Rifampin Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Figure 7.7 Tuberculosis Treatment Other Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030

Figure 8.1 Johnson & Johnson: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Figure 8.2 Lupin: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Figure 8.3 Macleods Pharmaceuticals Limited: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Figure 8.4 Pfizer: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Figure 8.5 Otsuka Pharmaceuticals: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025

Figure 9.1 Global Tuberculosis drugs Market Revenue ($million): 2019, 2025 and 2030

Figure 9.2 Leading Regional Markets Revenue ($million): 2019, 2025, and 2030

Download sample pages

Complete the form below to download your free sample pages for Global Tuberculosis Treatment Drugs Market Report 2020-2030

Download sample pages

Complete the form below to download your free sample pages for Global Tuberculosis Treatment Drugs Market Report 2020-2030

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

31 May 2023

READ

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

26 May 2023

READ

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

24 May 2023

READ

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

23 May 2023

READ

Industries > Pharma > Global Tuberculosis Treatment Drugs Market Report 2020-2030

Back to Pharma Reports

Global Tuberculosis Treatment Drugs Market Report 2020-2030

Download sample pages

Related reports

Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020

Nasal Drug Delivery Technology Market Forecast 2020-2030

Clinical Trial Supply and Logistics Market for Pharma 2020-2030

Vaccine Contract Manufacturing Market Forecast 2020-2030

Pharmaceutical Packaging Market Report 2018-2028

Pharmaceutical Contract Manufacturing Market 2019-2029

Needle-Free Delivery Technology Market 2018-2028

Drug Delivery Technologies Market Forecast 2019-2029

Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029

Global Antibacterial Drugs Market 2019-2029

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

Our Clients